Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005203947
Thu, 14.03.2024
BRAIN Biotech AG
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams
BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop sustainable, non-alcoholic beverages from agricultural side streams
Consortium reaps benefits of new grape varieties adapted to climate change
Lif [ … ]
Tue, 12.03.2024
BRAIN Biotech AG
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
Face-to-face event at the Zwingenberg site
Executive Board and Supervisory Board approved by a clear majority
Silent partnership with the State of Hesse approved by a very large majority
Zwingenberg, Germany, 12 March 2024 – At today´s Annual General Me [ … ]
Tue, 05.03.2024
BRAIN Biotech AG
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
First patent application registered
BRAIN Biotech relies on protein engineering expertise and bioinformatics for rational protein design
Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading [ … ]
Thu, 29.02.2024
BRAIN Biotech AG
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
Zwingenberg, Germany, 29 February 2024 – At its meeting today and with the approval of the Supervisory Board, the Management Board of BRAIN Biotech AG has resolved, to issue convertible bonds in the total nominal amount of EUR 5.0 [ … ]
Thu, 29.02.2024
BRAIN Biotech AG
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
BRAIN Biotech AG: issuance of EUR 5 million converti [ … ]
Wed, 28.02.2024
BRAIN Biotech AG
3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
Strong BioScience business in Q1
BioProducts growth to accelerate over the next quarters
Optimistic outlook for the business year targeting revenue range of € 58 million to € 62 million
Zwingenberg, Germany, 28. February 2024 – BRAIN Biotech AG, a lea [ … ]
Wed, 17.01.2024
BRAIN Biotech AG
Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy
Group sales grew by 11.8 %, 9.8 % all organic
All divisions contribute to growth
Successful execution of One-BioProducts strategy
Strong progress on BioIncubator pharmaceutical project Deucrictibant
Zwingenberg, Germany, 17. January 2024 – BRAIN Biotech AG, a leadi [ … ]
Mon, 20.11.2023
BRAIN Biotech AG
Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapyZwingenberg, Germany, 20 November, 2023 – The Akribion Genomics team of BRAIN Biotech AG has received the Hessian Founder Award and was also named the winner in its category. The biotech start-up succeeded against a total of 193 applicants from v [ … ]
Thu, 28.09.2023
BRAIN Biotech AG
BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competitionZwingenberg (Germany), 28 September 2023 – BRAIN Biotech AG is pleased to announce that its Akribion Genomics team has won the first prize in the “BioRiver Boost! 2023” startup competition for life science founders. The jury awarded the prize for [ … ]
Thu, 14.09.2023
BRAIN Biotech AG
BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®Zwingenberg, Germany, 14 September 2023 – BRAIN Biotech AG today announced that the European Patent Office has issued a new patent covering BRAIN’s G-dase E® nucleases as a composition of matter patent.
BRAIN Biotech's Akribion Genomic [ … ]